RecruitingPhase 3NCT05948475
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
Studying Cholangiocarcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- TransThera Sciences (Nanjing), Inc.
- Principal Investigator
- Milind Javle, MD, M.DM.D. Anderson Cancer Center
- Intervention
- Tinengotinib 8 mg(drug)
- Enrollment
- 200 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (30)
- UCLA Medical Center, Santa Monica, California, United States
- Stanford Cancer Center, Stanford, California, United States
- The University of Kansas Cancer Center, Westwood, Los Angeles, California, United States
- Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
- The University of Chicago Hospitals, Chicago, Illinois, United States
- UMass Memorial Medical Center, Worcester, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Henry Ford, Detroit, Michigan, United States
- University of Minnesota- Masonic Cancer Center, M Health Fairview, Minneapolis, Minnesota, United States
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
- Messino Cancer Centers, Asheville, North Carolina, United States
- University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
- Tennessee Oncology- Nashville, Nashville, Tennessee, United States
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05948475 on ClinicalTrials.govOther trials for Cholangiocarcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07478523FAPI-PET Value for the Initial Screening of Pancreatic and Biliary CancersUniversity Hospital, Bordeaux
- RECRUITINGNANCT07476651Scout Dose of Resin MicrospheresSeoul National University Hospital
- RECRUITINGPHASE2NCT06728410A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementMehmet Akce
- RECRUITINGPHASE2NCT07201519Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion ChemotherapyMichael J Cavnar, MD
- RECRUITINGPHASE2NCT07223307REGULUS: MRI-guided Adaptive SABR for Liver CancersStanford University
- RECRUITINGPHASE2NCT07260175Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 CholangiocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- RECRUITINGNANCT06735560Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NENNantes University Hospital
- RECRUITINGNANCT07263217Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver InjurySecond Affiliated Hospital, School of Medicine, Zhejiang University